$0.04 EPS Expected for Crispr Therapeutics AG (NASDAQ:CRSP) This Quarter
Wall Street brokerages expect Crispr Therapeutics AG (NASDAQ:CRSP) to announce earnings of $0.04 per share for the current quarter, according to Zacks. Three analysts have made estimates for Crispr Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.07. Crispr Therapeutics posted earnings of ($0.92) per share during the same quarter last year, which indicates a positive year over year growth rate of 104.3%. The business is scheduled to issue its next earnings report on Monday, February 24th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of $0.65 per share for the current financial year, with EPS estimates ranging from $0.59 to $0.71. For the next year, analysts expect that the business will post earnings of ($4.65) per share, with EPS estimates ranging from ($5.38) to ($3.77). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
CRSP stock traded down $1.82 during mid-day trading on Thursday, reaching $56.57. The company had a trading volume of 1,032,126 shares, compared to its average volume of 1,104,019. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock has a 50 day simple moving average of $63.51 and a two-hundred day simple moving average of $52.46. The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of -122.98 and a beta of 3.20. Crispr Therapeutics has a 52 week low of $29.34 and a 52 week high of $74.00.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 over the last quarter. 21.40% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management LLC acquired a new stake in Crispr Therapeutics during the 2nd quarter worth approximately $5,165,000. Webster Bank N. A. acquired a new stake in Crispr Therapeutics during the 4th quarter worth approximately $26,000. State Street Corp lifted its holdings in Crispr Therapeutics by 2.1% during the 3rd quarter. State Street Corp now owns 37,103 shares of the company’s stock worth $1,521,000 after purchasing an additional 758 shares during the last quarter. Millennium Management LLC acquired a new stake in Crispr Therapeutics during the 3rd quarter worth approximately $4,366,000. Finally, Bank of New York Mellon Corp lifted its holdings in Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after purchasing an additional 17,810 shares during the last quarter. Institutional investors own 49.83% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.